CoreWeave Set To Acquire Core Scientific For $9 Billion – The Special Situations Report Episode #27

Episode Summary

Executive Summary: Episode 27 surveys a busy week in special situations, led by CoreWeave’s all-stock acquisition of Core Scientific and its unusually wide merger spread, plus several biotech, food, mining, software, and governance events. The hosts emphasize how deal terms, cash-rich balance sheets, insider activity, and management succession can create opportunities—or signal skepticism—in event-driven investing.

Main Topics: CoreWeave acquires Core Scientific (Priority: 5/5): The central topic is CoreWeave’s $9B all-stock purchase of Core Scientific, notable for large pre-announcement rumors, a post-deal stock drop, and a wide spread driven by shorting difficulty and investor disappointment versus rumored higher pricing. Cash-rich biotech 'zombie' acquisition: Cargo Therapeutics (Priority: 5/5): Concentra Biosciences continues buying biotech companies trading below cash, agreeing to acquire Cargo Therapeutics with a CVR designed to distribute excess cash rather than reward drug development milestones. Consumer and gold-industry consolidation (Priority: 4/5): The episode covers Ferrero buying WK Kellogg, Kraft Heinz exploring a spin-off, and Sandstorm Gold merging with Royal Gold, highlighting consolidation in food and mining as companies seek value creation and scale. Merck’s all-cash acquisition of Verona Pharma (Priority: 4/5): Merck’s $10B purchase of Verona Pharma is highlighted as a more straightforward biotech/pharma deal without a CVR, with a closing expected by year-end and a respiratory-disease asset base. Buybacks and fintech platform strength at The Bancorp (Priority: 4/5): The Bancorp’s large $500M buyback is presented as meaningful given its size and history of execution, underscoring how some niche financial platforms have rewarded shareholders strongly. Insider transactions and leadership changes (Priority: 4/5): The hosts discuss heavy insider selling at large tech firms, Oracle board director Baroness Fairhead’s small purchase, and leadership transitions at Baxter, Sinclair, and Apple as potential signals for future performance. Media and software M&A speculation (Priority: 3/5): Bloomberg reports on possible interest in Lionsgate from Legendary Entertainment and speculation that Autodesk may pursue PTC, with both cases viewed through valuation and regulatory-lens skepticism.

Key Arguments: Core Scientific’s valuation and the 40%+ spread reflect market disappointment that the deal was not priced as high as rumored and the inability to easily short CoreWeave. Core Scientific’s reported Q1 profit was driven largely by mark-to-market accounting gains, not core operating improvement, which may reverse later in the year. Concentra’s biotech strategy is not about drug pipelines but about extracting excess cash from companies trading below net cash. WK Kellogg’s premium is part of a broader food consolidation trend, especially after its prior spin-off from Kellanova. Gold mining companies may lag the metal because of higher costs and depleting mines, making M&A a logical response. The Bancorp’s platform model and consistent buybacks make it an unusually effective niche financial compounder. Danaher alumni are viewed as especially credible turnaround operators, making Baxter’s new CEO appointment noteworthy. Oracle’s insider selling is not necessarily bearish because it reflects heavy equity compensation; Baroness Fairhead’s small buy is unusual given the stock’s run-up. Broadcasting companies may get a second wind under a more M&A-friendly FCC environment. Apple’s succession planning appears orderly, with an internal promotion preserving operational continuity despite concerns about innovation. Lionsgate and PTC remain speculative M&A names, but regulatory and valuation hurdles temper enthusiasm.

Data Points: Core Scientific deal value: $9 billion - All-stock acquisition by CoreWeave Core Scientific spread: Over 24% - Spread remained wide after announcement; at one point exceeded 40% Core Scientific pre-announcement stock move: From a little over $12 to $18 per share - Stock ran up on rumors before the deal was announced Core Scientific Q1 2025 revenue change: Down 56% year over year - Revenue declined for the fourth sequential quarter Core Scientific Q1 2025 net income: $581 million ($1.25/share) - Driven primarily by mark-to-market adjustments on warrants and CVRs CoreWeave revenue concentration: 62% of revenue from Microsoft - Microsoft was a major customer in 2024 CoreWeave revenue: About $1.2 billion - Referenced in discussion of Microsoft concentration CoreWeave stock performance: Up more than 200% in the last three months - Following its April IPO Cargo Therapeutics acquisition price: $4.38 per share - Concentra Biosciences deal Cargo Therapeutics deal value: Almost $171 million - Despite market cap and cash being higher than purchase price Cargo Therapeutics market cap: $214 million - Compared with net cash on balance sheet Cargo Therapeutics net cash: About $288 million - Balance sheet cash exceeded equity purchase price Sandstorm Gold / Royal Gold deal value: $3.5 billion - All-stock merger in mining sector Sandstorm Gold spread: Less than 2% - Deal spread was relatively tight Verona Pharma deal value: $10 billion - Merck’s all-cash acquisition WK Kellogg deal value: $3.1 billion - Ferrero’s acquisition WK Kellogg offer price: $23 per share in cash - Company also noted as a Kellanova spin-off WK Kellogg stock reaction: Up 37% since announcement - Resulting in spread of less than 1% Bancorp buyback authorization: $500 million - Nearly 18% of market cap at announcement Bancorp prior buyback authorization: $100 million total - Included a prior $50 million increase in 2024 Bancorp share reduction: 19% over four years - Shows execution on capital returns Bancorp stock return: Up about 630% over five years - Strong long-term performance Oracle insider selling: $1.56 billion - Safra Katz sold stock after option exercises Oracle stock performance: Up 61% over the last year; over 300% over five years - Used to contextualize selling and compensation Oracle insider purchase: $100,000 - Baroness Fairhead bought shares Mueller Water Products insider purchase: $27,000 - Director Brian Healy buy during quiet period Mueller Water Products gross margin: 34% - Described as strong for a manufacturing company Mueller Water Products net margin: 10% - Despite being a manufacturing business Mueller Water Products revenue growth: Nearly 11% last year - Steady operational improvement Mueller Water Products market cap: $4 billion - With relatively little net debt Mueller Water Products dividend yield: 1.05% - Small dividend included in the analysis GE stock return under Danaher alumnus Larry Culp: 666% over five years - Illustrates the perceived value of Danaher-trained executives Baxter CEO start date: September 3, 2025 - Andrew Hilder to begin as CEO ATS stock performance under Andrew Hilder: Up 191% in eight years - Used to support turnaround credentials Sinclair new CFO: Narender Sahai - CFO transition after retirement announcement Apple stock return during Jeff Williams tenure: 745% - Williams stepping down from COO role in planned succession Apple COO transition: Jeff Williams to Sabi Khan - Internal promotion with design team eventually reporting to Tim Cook

Pivotal Quotes: "the spread on this deal increased over 40%" — Asif Suria: Describing CoreWeave/Core Scientific market reaction after announcement "the company seems to be focused on acquiring Zombie Biotechs" — Asif Suria: Characterizing Concentra Biosciences’ strategy of buying biotech firms trading below cash "The times change." — Namanda Surya: Reaction to the scale of Oracle insider selling compared with earlier eras

Implications: Investors should watch for merger spreads distorted by shorting constraints, cash-rich biotech liquidations, and management/succession signals. The episode suggests more consolidation ahead in food, mining, media, and broadcasting, with insider behavior and capital allocation remaining key event-driven cues.